| | 152121-30-7 Basic information More.. |
| Product Name: | SB 202190 | | Synonyms: | 4-[4-(4-FLUOROPHENYL)-5-(4-PYRIDINYL)-1H-IMIDAZOL-2-YL]PHENOL;4-(4-FLUOROPHENYL)-2-(4-HYDROXYPHENYL)-5-(4-PYRIDYL)-1H-IMIDAZOLE;4-(4-(4-fluorophenyl)-5-(pyridin-4-yl)-2H-imidazol-2-yl)phenol;Aids110355;Aids-110355;Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-;SB 202190;SB 202190,4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole | | CAS: | 152121-30-7 | | MF: | C20H14FN3O | | MW: | 331.34 | | EINECS: | | | Mol File: | 152121-30-7.mol |  |
Use
SB 202190 is a DFG inhibitor used in the treatment of colorectal cancer. It is a highly selective, potent inhibitor of p38 MAP kinase. SB-202190 is able to promote proliferation of C6 cells in lower c
oncentration but induced apoptosis in higher levels. Studies show that SB202190 can protect neural function from ischemia/reperfusion injury and regulate the activation of Bcl-2 and Bax protein after
ischemia/reperfusion in rat.
- SB 202190
-
- US $1.10 / g
- 2021-09-27
- CAS:152121-30-7
- Min. Order: 1g
- Purity: 99.00%
- Supply Ability: 100 Tons Min
- SB 202190
-
- US $1.00 / KG
- 2019-07-06
- CAS:152121-30-7
- Min. Order: 1KG
- Purity: 98-100%
- Supply Ability: 1000kg
|
|
152121-30-7
Recommend Suppliers |
|